

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/15501496>

# Aspartate mutation distinguishes ETA but not ETB receptor subtype-selective ligand binding while abolishing phospholipase C activation in both receptors

ARTICLE *in* FEBS LETTERS · APRIL 1995

Impact Factor: 3.17 · DOI: 10.1016/0014-5793(95)00164-5 · Source: PubMed

---

CITATIONS

31

---

READS

22

8 AUTHORS, INCLUDING:



[Stanley R Krystek](#)

Bristol-Myers Squibb

55 PUBLICATIONS 1,597 CITATIONS

SEE PROFILE

# Aspartate mutation distinguishes ET<sub>A</sub> but not ET<sub>B</sub> receptor subtype-selective ligand binding while abolishing phospholipase C activation in both receptors

Patricia M. Rose<sup>a</sup>, Stanley R. Krystek Jr.<sup>b</sup>, Pramathesh S. Patel<sup>a</sup>, Eddie C.K. Liu<sup>c</sup>, Jean S. Lynch<sup>a</sup>, David A. Lach<sup>a</sup>, Susan M. Fisher<sup>a</sup>, Maria L. Webb<sup>c,\*</sup>

<sup>a</sup>Departments of Microbial Molecular Biology, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543, USA

<sup>b</sup>Macromolecular Modeling, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543, USA

<sup>c</sup>Cardiovascular Biochemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543, USA

Received 17 January 1995; revised version received 3 February 1995

**Abstract** The endothelin receptors, ET<sub>A</sub> and ET<sub>B</sub>, are G protein-coupled receptors (GPCR) that show distinctively different binding profiles for the endothelin peptides and other ligands. We recently reported that Tyr<sup>129</sup> in the second transmembrane region (TM2) of the ET<sub>A</sub> receptor was critical for subtype-specific ligand binding [Krystek, S.R. et al. (1994) *J. Biol. Chem.* 269, 12383–12386]. Receptor models indicated that aspartic acids located one helical turn above (Asp<sup>133</sup>) and below (Asp<sup>126</sup>) Tyr<sup>129</sup> in ET<sub>A</sub> had their side chains directed toward the putative binding cavity. Similarly in ET<sub>B</sub>, Asp<sup>147</sup> and Asp<sup>154</sup> are located one turn below and above His<sup>150</sup>, the residue that corresponds to Tyr<sup>129</sup>. Asp<sup>126</sup> in ET<sub>A</sub> and Asp<sup>147</sup> in ET<sub>B</sub> correspond to the highly conserved aspartate present in TM2 of many GPCR that has frequently been shown to be crucial for agonist efficacy. Mutagenesis of Asp<sup>126</sup> of the human ET<sub>A</sub> receptor to alanine resulted in an unaltered affinity for ET-1, a 160-fold increase in ET-3 affinity and a decrease in affinity for the ET<sub>A</sub> selective naphthalenesulfonamide, BMS-182874. ET-1 activation of phospholipase C was abolished. In addition, despite the gain in binding affinity, ET-3 failed to activate phospholipase C, suggesting that Asp<sup>126</sup> is required for signal transduction. Mutagenesis of Asp<sup>133</sup> to alanine indicated that it was critical only for the binding of BMS-182874. In the ET<sub>B</sub> receptor, mutation of His<sup>150</sup> to alanine or tyrosine indicated that it plays a minor role in ET<sub>B</sub> subtype-selective ligand binding; mutation of the aspartates in TM2 of ET<sub>B</sub> did not alter ligand binding. As in the Asp<sup>126</sup>Ala ET<sub>A</sub> variant, ET-1 and ET-3 failed to increase intracellular levels of inositol phosphates in the Asp<sup>147</sup>Ala ET<sub>B</sub> mutant. Taken together, these data support the hypothesis that Asp<sup>126</sup> and Asp<sup>133</sup> flanking Tyr<sup>129</sup> in TM2 of the ET<sub>A</sub> receptor play a role in defining ET<sub>A</sub> subtype-selective ligand binding but Asp<sup>147</sup> and Asp<sup>154</sup> that flank the His<sup>150</sup> in TM2 of the ET<sub>B</sub> receptor do not. Furthermore, these data indicate that Asp<sup>126</sup> in ET<sub>A</sub> and Asp<sup>147</sup> in ET<sub>B</sub> are important for transmembrane signaling via phospholipase C.

**Key words:** Endothelin receptor; G protein-coupled receptor; Site-directed mutagenesis; Radioligand binding; Molecular modeling; Phospholipase C

## 1. Introduction

Endothelins (ETs) are a family of peptides that mediate di-

verse and potent biological activity in mammals through at least two distinct heptahelical G protein-coupled, cell surface receptors. The ET<sub>A</sub> subtype binds ET-1, the cyclic pentapeptide antagonist BQ-123, and the naphthalenesulfonamide antagonist, BMS-182874, preferentially, whereas ET<sub>B</sub> binds ET-1, ET-3 and sarafotoxin S6c with approximately equal affinity [1–4]. Ro 46–2005 and Ro 47–0203 are pyrimidinyl naphthalenesulfonamide antagonists that bind both receptor subtypes with equal affinity [5,6]. SB 209670 is an indanecarboxylic acid that binds ET<sub>A</sub> and ET<sub>B</sub> receptors with high affinity [7]. Due to the potent biological activities of the ET peptides, inhibition of their action through receptor antagonism has been proposed as a point for therapeutic intervention in numerous cardiovascular diseases.

Elucidation of receptor amino acids involved in ligand binding and signal transduction is critical to understanding the mechanism of ligand–receptor–G protein interactions and may facilitate drug design. Evidence from chimeric ET<sub>A</sub>/ET<sub>B</sub> receptors indicates that transmembrane regions 1, 2, 3, and 7 [8] and the first extracellular loop [9] may contain a binding site for BQ-123. Takasuka et al. [10] reported that a 29 amino acid segment of the ET<sub>B</sub> N-terminus adjacent to the first transmembrane region was important for ET-1 binding while Zhu et al. [11] reported that the lysine in TM3 of ET<sub>B</sub> was important for ET isopeptide binding and critical for sarafotoxin S6c binding. Finally, Adachi et al. [12] suggested that Lys<sup>140</sup> of the ET<sub>A</sub> receptor is important for ET-1 binding. This residue is thought to be located at or near the C-terminus (extracellular side) of TM2. Recently, we and others reported that Tyr<sup>129</sup> in TM2 of the ET<sub>A</sub> receptor is critically involved in subtype-selective ligand binding [13,14]. Mutation of Tyr<sup>129</sup> to alanine or to histidine, the corresponding amino acid in ET<sub>B</sub>, resulted in a binding profile characteristic of an ET<sub>B</sub> receptor. In addition, this represented one of the first indications that amino acids in the transmembrane regions are in contact with ET isopeptides as well as non-peptidic ligands [11,13–14].

Inspection of the sequence of TM2 in the human ET<sub>A</sub> receptor indicated that there are two aspartate residues flanking Tyr<sup>129</sup>; one is a turn above (Asp<sup>133</sup>) and the other is a turn below (Asp<sup>126</sup>) in the transmembrane helix. A similar configuration is present in ET<sub>B</sub>, with Asp<sup>147</sup> and Asp<sup>154</sup> flanking His<sup>150</sup>. The Asp<sup>126</sup> in ET<sub>A</sub>, or Asp<sup>147</sup> in ET<sub>B</sub>, is conserved in many GPCR [15] and has been shown to be important in agonist binding and/or signal transduction in several receptors [16–20]. According to our computer generated three-dimensional model of the

\*Corresponding author. Fax: (1) (609) 252 6964.

**Abbreviations:** TM2, second transmembrane region; ET, endothelin; IP, inositol phosphate; PLC, phospholipase C.

ET<sub>A</sub> receptor and our previous studies of Tyr<sup>129</sup> in the ET<sub>A</sub> subtype-selective ligand binding, we hypothesized that the side chains of these aspartates are directed toward the putative binding cavity and may be involved in ligand binding and G protein-coupled signaling. To test these hypotheses and to investigate the role of the aspartate-tyrosine-aspartate and aspartate-histidine-aspartate helical turns in subtype-selective ligand binding, Asp<sup>126</sup>Ala and Asp<sup>133</sup>Ala ET<sub>A</sub> mutants, as well as Asp<sup>147</sup>Ala and Asp<sup>154</sup>Ala ET<sub>B</sub> mutants, were prepared and the binding affinities of a panel of ET receptor ligands were evaluated. Phosphoinositide turnover was measured in Asp<sup>126</sup>Ala and Asp<sup>147</sup>Ala mutants to assess agonist efficacy. We show here that mutation of Asp<sup>126</sup> to alanine causes an increase in the affinity of the ET<sub>B</sub> selective agonist, ET-3, and a decrease in the affinity of the ET<sub>A</sub> selective antagonist, BMS-182874. Mutation of Asp<sup>133</sup> to alanine only causes a decrease in the affinity of BMS-182874. In contrast, mutagenesis of the analogous aspartates in ET<sub>B</sub>, Asp<sup>147</sup> and Asp<sup>154</sup>, failed to affect the ET<sub>B</sub> receptor binding profile, demonstrating that TM2 is important in defining ET<sub>A</sub> but not ET<sub>B</sub> subtype selective ligand binding. In addition, we show that phospholipase C activation is abolished in the Asp<sup>126</sup>Ala ET<sub>A</sub> and Asp<sup>147</sup>Ala ET<sub>B</sub> mutants, indicating that, despite their differing importance in ligand binding, these residues play a critical role in transmembrane signaling in both receptor subtypes.

## 2. Materials and methods

### 2.1. Materials

Restriction enzymes and DNA modifying enzymes were from Promega (Madison, WI). The pACYC184 vector was obtained from New England BioLabs (Beverly, MA); the pCDM8 vector was from Invitrogen (San Diego, CA). The Transformer site-directed mutagenesis system was obtained from Clontech (Palo Alto, CA). The MutaGene Phagemid in vitro Mutagenesis kit was obtained from BioRad (Hercules, CA). COS-7 cells were obtained from ATCC (Rockville, MD); tissue culture reagents and Lipofectamine were from Life Technologies, Gibco/BRL (Gaithersburg, MD). [<sup>125</sup>I]ET-1 (2,200 Ci/mmol) was obtained from DuPont NEN (Boston, MA), ET-1, ET-3 and sarafotoxin S6c from Peninsula Labs. Other biochemical reagents were obtained from Sigma (St. Louis, MO).

### 2.2. Model building

The construction of the ET<sub>A</sub> and ET<sub>B</sub> receptor models was performed as described previously [13]. Briefly, sequences of the receptor subtypes were aligned and the transmembrane regions identified by pairwise comparisons based on hydrophobicity conservation. The putative transmembrane sequences were then threaded through a helix bundle which was derived from the coordinates of bacteriorhodopsin [21]. For this model the kinks found in the bacteriorhodopsin helices were removed and the helices were kinked based on the location of prolines in the ET receptor sequences. Geometry of the new seven helix bundle was refined as described [13]. Molecular modeling was conducted with INSIGHT and DISCOVER (Biosym Technologies, San Diego, CA) performed on a Silicon Graphics 4D/440 work station. Model analysis and display was conducted interactively using GRASP [22].

### 2.3. Mutagenesis

Site-directed mutagenesis of the human placental ET<sub>A</sub> receptor [23] was conducted in our laboratory according to Deng and Nickoloff [24] and has been described elsewhere [13]. Mutagenesis of the human placental ET<sub>B</sub> receptor [25] was conducted according to Kunkel [26]. Briefly, the ET<sub>B</sub> cDNA in pCDM8 was grown in the dut<sup>-</sup>ung<sup>-</sup> CJ236 strain of *E. coli*, resulting in DNA carrying a number of uracil containing nucleotides in place of thymine, and single stranded DNA was isolated. A mutagenic oligonucleotide was annealed to the uracil containing single stranded template and the complementary strand was synthesized in vitro. When this double stranded DNA was transformed

into dut<sup>+</sup>ung<sup>+</sup> MV1190 *E. coli*, the uracil containing strand was inactivated and the non-uracil containing, presumably mutant, strand was replicated. Mutant plasmids were initially identified by restriction analysis and subsequently verified by sequencing the entire cDNA insert using the dideoxy sequencing method of Sanger et al. [27].

### 2.4. Receptor expression and binding

Wild-type and mutant ET<sub>A</sub> and ET<sub>B</sub> receptor cDNAs were transfected into COS-7 cells using the polycationic lipid Lipofectamine according to the manufacturer's instructions. COS-7 cells were routinely maintained in a growth medium of Dulbecco's modified essential medium (DMEM) containing 10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 mg/ml). Transfection of COS-7 cells with a CMV/αgal plasmid indicated a transfection efficiency of 5–20%. Cells were harvested 48–72 h after transfection and membranes were prepared as previously described [13]. [<sup>125</sup>I]ET-1 (50 pM) binding assays were performed as described previously [2] with specific binding defined in the presence of 100 nM ET-1. Data were analyzed by iterative curve fitting to a one binding site model.

### 2.5. Measurement of phosphoinositide turnover

COS-7 cells were seeded in 6-well plates (1–3 × 10<sup>4</sup> cells/well) in growth medium, and transfected as described above. Two to six hours following removal of transfection reagents, cells were labeled with [<sup>3</sup>H]myoinositol (8 μCi/ml) for 48–72 h. Cell monolayers were washed and incubated for 15 min in DMEM containing 20 mM LiCl and 0.1% bovine serum albumin. Cells were treated with ET-1 for 15 min and the media removed. Boiling EDTA (2 mM) was added to the cell monolayer to disrupt cell integrity and release soluble inositol phosphate (IP). The resulting mixture was applied to a Dowex AG 1 × 8 anion exchange column and total IP was collected as described [28]. Eluant was counted in a Packard Tri-Carb 4640 scintillation counter at 40% efficiency. As a control for expression efficiency, specific [<sup>125</sup>I]ET-1 binding (50 pM) was assessed concomitantly in COS-7 cells transfected with wild-type or mutant cDNA. Following the binding reaction, the cells were washed and transferred in 500 μl of 0.5 N NaOH to a Packard Gamma counter for measurement of radioactivity.

### 2.6. Statistical analysis

Data are expressed as mean ± standard error (S.E.) from three or more determinations.

## 3. Results

### 3.1. Binding to the Asp<sup>126</sup>Ala and Asp<sup>133</sup>Ala ET<sub>A</sub> receptor mutants

Previous results with Tyr<sup>129</sup> ET<sub>A</sub> receptor mutants [13] indicated that TM2 contributes to 'fine selectivity' of ligand binding to ET receptors. Based on the same ET<sub>A</sub> receptor model, two aspartate residues located approximately one helical turn above and below the Tyr<sup>129</sup> (Fig. 1A), are oriented in a manner similar to the tyrosine with their side chains directed toward the putative ligand binding pocket (Fig. 1B). Asp<sup>133</sup> and Asp<sup>126</sup> are postulated to be approximately six and thirteen amino acid residues from the extracellular surface respectively. Alanines were substituted at each position and the resulting ET<sub>A</sub> receptor mutants, Asp<sup>126</sup>Ala and Asp<sup>133</sup>Ala, were expressed in COS-7 cells. The affinity of peptidic agonists and antagonists and non-peptidic antagonists for the mutant receptors was compared to that for wild-type ET<sub>A</sub> and ET<sub>B</sub> receptors. Based on energetic criteria, ten-fold or greater alterations in affinity from control were generally considered relevant [13,29]. Inhibition of specific [<sup>125</sup>I]ET-1 binding in membranes from transiently transfected COS-7 cells indicated that the affinity of ET-1 and ET-2 were not altered by either the Asp<sup>126</sup>Ala or Asp<sup>133</sup>Ala mutations (Table 1), suggesting that the mutant receptors have not undergone a general or large scale structural rearrangement. However, the affinity of ET-3 for the Asp<sup>126</sup>Ala ET<sub>A</sub> receptor was





Fig. 1. Human ET<sub>A</sub> and ET<sub>B</sub> receptor models and corresponding amino acid sequences. Panel A: primary structure of human (h), bovine (b), rat (r) and porcine (p) ET<sub>A</sub> and ET<sub>B</sub> receptor sequences corresponding to predicted TM2 (indicated by the boxed residues). Numbering is according to the ET<sub>A</sub> receptor. Panel B: comparison of the superimposed models of the second TM2 of the ET<sub>A</sub> and ET<sub>B</sub> receptors. Shown is the least-squares superposition (of backbone atoms) for ET<sub>A</sub> and ET<sub>B</sub> displayed using ribbon representation for backbone atoms of transmembrane region 7 (TM7), 2 (TM2) and 3 (TM3). The aspartates and tyrosine/histidine residues in TM2 of ET<sub>A</sub>/ET<sub>B</sub> are displayed as well as Lys<sup>166</sup>/Lys (ET<sub>A</sub>/ET<sub>B</sub>) as a point of reference. The insert to panel B shows an axial view of the helices with side chains directed towards the putative ligand binding cavity.




Fig. 2. Effects of ET-1 and ET-3 on inositol phosphate accumulation in COS-7 cells expressing the wild-type and mutant ET<sub>A</sub> receptors. Panel A: COS-7 cells expressing the wild-type (solid symbols and lines) or Asp<sup>126</sup>Ala (open symbols and dashed lines) ET<sub>A</sub> receptors were treated with increasing concentrations of ET-1 (circles) and ET-3 (triangles) for 15 min. IP production was measured as described in section 2. Results are representative of three similar experiments and data points are the mean of duplicate determinations. Panel B: comparison of expression levels of wild-type and Asp<sup>126</sup>Ala ET<sub>A</sub> receptors in transiently transfected COS-7 cells. Specific [<sup>125</sup>I]ET-1 (50 pM) binding was determined in the absence and presence of 100 nM ET-1. Data are expressed as the mean ± S.E.M. of specific [<sup>125</sup>I]ET-1 binding in three experiments and were normalized to percent of wild-type levels.

improved approximately 160-fold while the affinity of BMS-182874 decreased 20-fold (Table 1). Since ET-3 is approximately 1,000-fold selective for the ET<sub>B</sub> receptor subtype and BMS-182874 is approximately 1,000-fold selective for the ET<sub>A</sub> receptor subtype [4], these findings support the hypothesis that Asp<sup>126</sup> plays a role in subtype selective ligand–receptor interactions.

In contrast to the Asp<sup>126</sup>Ala binding profile, ligand affinities for the Asp<sup>133</sup>Ala ET<sub>A</sub> mutant were largely unchanged from wildtype values with the exception of that for BMS-182874 (Table 1). The binding affinity (IC<sub>50</sub>) for this antagonist decreased 70-fold from 340 nM to 25 μM.

### 3.2. Effects of mutation of Asp<sup>126</sup> on ET<sub>A</sub>-mediated phosphoinositide turnover

Recombinant wild-type ET<sub>A</sub> receptors stably expressed in CHO cells activate phospholipase C (PLC) as assessed by measurements of intracellular IP accumulation [1,30]. Previous investigations demonstrated that the conserved aspartate residue in TM2 (corresponding to Asp<sup>126</sup> in ET<sub>A</sub>) of the α<sub>2</sub>-adrenergic [16], β<sub>2</sub>-adrenergic [19], angiotensin AT<sub>1</sub> [18], lutropin [17] and opioid [20] receptors is crucial to signaling by agonist occupied receptors. Thus, the effect of alanine substitution for Asp<sup>126</sup> on PLC activation was examined. COS-7 cells transfected with the recombinant wild-type receptor or the Asp<sup>126</sup>Ala variant were treated with increasing concentrations of ET-1. Cells transfected with wild-type ET<sub>A</sub> responded to ET-1 treatment with

a concentration-dependent increase in total IP accumulation (EC<sub>50</sub> = 1 ± 0.6 nM). However, the IP response to ET-1 was abolished in Asp<sup>126</sup>Ala transfected cells (Fig. 2A). The ablation of the IP response was not due to differences in receptor expression because concomitant measurement of specific [<sup>125</sup>I]ET-1 binding to wild-type and Asp<sup>126</sup>Ala transfected cells was similar (Fig. 2B).

Given the 160-fold increase in ET-3 binding affinity for the Asp<sup>126</sup>Ala ET<sub>A</sub> receptor, it was of interest to determine if this ET<sub>B</sub>-selective agonist could activate PLC. As shown in Fig. 2A, ET-3 produced a concentration-dependent increase in IP accumulation in cells transfected with wild-type ET<sub>A</sub> cDNA. The estimated EC<sub>50</sub> agrees with the IC<sub>50</sub> value for ET-3 at the wild-type ET<sub>A</sub> receptor (EC<sub>50</sub> = 800 nM; IC<sub>50</sub> = 820 nM). However, ET-3 concentrations up to 1 μM failed to elicit an increase in intracellular IP levels above basal levels in COS-7 cells expressing the Asp<sup>126</sup>Ala ET<sub>A</sub> variant where the IC<sub>50</sub> for ET-3 improved to 5 nM. Thus, the gain in ET-3 binding affinity observed in the Asp<sup>126</sup>Ala mutant did not result in a gain in ET-3-induced functional activity.

### 3.3. Binding to Asp<sup>147</sup>Ala, His<sup>150</sup>Ala, His<sup>150</sup>Tyr, and Asp<sup>154</sup>Ala ET<sub>B</sub> mutants

As it became clear that TM2 in ET<sub>A</sub> played an important role in ligand–receptor–G protein interactions, the question arose as to whether the corresponding region in ET<sub>B</sub> played a similar role. Examination of TM2 (Fig. 1A) of all currently cloned ET<sub>A</sub>

Table 1  
Inhibition of specific [<sup>125</sup>I]ET-1 binding (50 pM) to Asp<sup>126</sup>Ala and Asp<sup>133</sup>Ala ET<sub>A</sub> receptor mutants

Agent	Wild-type ET <sub>A</sub>	Asp <sup>126</sup> Ala ET <sub>A</sub>	Asp <sup>133</sup> Ala ET <sub>A</sub>	Wild-type ET <sub>B</sub>
ET-1	0.4 ± 0.2	0.2 ± 0.06	0.8 ± 0.12	0.2 ± 0.0
ET-2	0.4 ± 0.04	1.8 ± 0.2	1.6 ± 0.2	0.2 ± 0.0
ET-3	820 ± 260	5.0 ± 1.2	600 ± 40	0.4 ± 0.2
S6c	29,000 ± 4,000	12,100 ± 1,700	6,600 ± 320	0.3 ± 0.1
BQ-123	40 ± 6	320 ± 40	40 ± 1	66,000 ± 2,400
BMS-182874	340 ± 60	7,600 ± 200	25,000 ± 2,200	110,000 ± 27,000
Ro 47-0203	20 ± 4	40 ± 5	60 ± 6	160 ± 40

Values are inhibition constants (IC<sub>50</sub>) in nM ± S.E.M. (n ≥ 3). Binding to the wild-type ET<sub>A</sub> and ET<sub>B</sub> receptors is shown for comparison.




Fig. 3. Effects of ET-1 and ET-3 on inositol phosphate accumulation in COS-7 cells expressing the wild-type and mutant ET<sub>B</sub> receptors. Panel A: COS-7 cells expressing the wild-type (solid symbols and lines) or Asp<sup>147</sup>Ala (open symbols and dashed lines) ET<sub>B</sub> receptors were treated with increasing concentrations of ET-1 (circles) and ET-3 (triangles) for 15 min. IP production was measured as described in section 2. Results are representative of three similar experiments and data points are the mean of duplicate determinations. Panel B: comparison of expression levels of wild-type and Asp<sup>147</sup>Ala ET<sub>B</sub> receptors in transiently transfected COS-7 cells. Specific [<sup>125</sup>I]ET-1 (50 pM) binding was determined in the absence and presence of 100 nM ET-1. Data are expressed as the mean ± S.E.M. of specific [<sup>125</sup>I]ET-1 binding in three experiments and were normalized to percent of wild-type levels.

and ET<sub>B</sub> receptors shows a single major non-conservative amino acid difference: Tyr<sup>129</sup> in ET<sub>A</sub> is His<sup>150</sup> in ET<sub>B</sub>. All other sequence differences are conservative replacements (ET<sub>A</sub>/ET<sub>B</sub>: Ile<sup>128</sup>/Leu, Val<sup>130</sup>/Ile, Val<sup>131</sup>/Ile, Leu<sup>134</sup>/Ile) except for Ala<sup>117</sup>/Ile and Val<sup>138</sup>/Thr. Val<sup>138</sup> of human ET<sub>A</sub> and Thr<sup>159</sup> in human ET<sub>B</sub> are of similar size while both Ala<sup>117</sup> and the corresponding ET<sub>B</sub> amino acid, Ile<sup>138</sup>, are neutral, hydrophobic, aliphatic amino acids. Thus, both of these replacements can also be considered conservative. Therefore, except for the tyrosine/histidine divergence one might expect the configuration of side chains in TM2 to be similar in ET<sub>A</sub> and ET<sub>B</sub>. Interestingly, the aspartic acids in TM2 of ET<sub>A</sub> (Asp<sup>126</sup> and Asp<sup>133</sup>), hypothesized to be facing the putative binding cavity, are conserved in ET<sub>B</sub> (Asp<sup>147</sup> and Asp<sup>154</sup>) (Fig. 1B). These considerations suggested that it might be informative to mutate the histidine and aspartate residues in TM2 of ET<sub>B</sub> to alanine. In addition, His<sup>150</sup> was mutated to tyrosine, the amino acid present in the ET<sub>A</sub> receptor.

Compared to the wild-type ET<sub>B</sub> receptor, ligand affinities to the Asp<sup>154</sup>Ala and Asp<sup>147</sup>Ala ET<sub>B</sub> mutants did not show greater than 10-fold changes (Table 2). On the other hand, when His<sup>150</sup> was mutated to alanine, the binding affinity for sarafotoxin S6c decreased 30-fold from 0.3 nM to 8 nM. Moreover, mutation of this histidine residue to tyrosine led to a decreased affinity of 10- to 200-fold for ET-3 and sarafotoxin S6c respectively. Thus, as the amino acid at position 150 of TM2 became more ET<sub>A</sub>-like, the affinity for ET<sub>B</sub> selective peptides was reduced. Interestingly, binding of the ET<sub>A</sub>/ET<sub>B</sub> non-selective sulfonamide Ro 47-0203 decreased approximately 10-fold in the His<sup>150</sup>Ala mutant. These findings are consistent with the sugges-

tion that His<sup>150</sup> in TM2 of ET<sub>B</sub> is involved in high affinity binding of the ET<sub>B</sub> selective agonists, ET-3 and sarafotoxin S6c, and provides some interaction for the non-selective antagonist Ro 47-0203.

### 3.4. Effects of mutation of Asp<sup>147</sup> on ET<sub>B</sub>-mediated phosphoinositide turnover

Despite the lack of effects that mutation of Asp<sup>147</sup> had on agonist binding affinity, it was of interest to determine if Asp<sup>147</sup>Ala ET<sub>B</sub> receptors had altered agonist efficacy. Similar to ET<sub>A</sub> receptors, recombinant ET<sub>B</sub> receptors that are stably expressed in CHO cells activate PLC as assessed by measurements of IP accumulation [1,30]. In the present experiments, treatment of COS-7 cells transiently expressing wild-type ET<sub>B</sub> receptors with ET-1 and ET-3 led to a concentration-dependent increase intracellular IP (Fig. 3A). The EC<sub>50</sub> values for the ET-1 and ET-3 induced-responses were 0.2 ± 0.1 nM and 0.6 ± 0.4 nM, respectively. However, both agonists failed to increase IP levels in COS-7 cells expressing Asp<sup>147</sup>Ala ET<sub>B</sub> receptors (Fig. 3A). Concomitant experiments demonstrated that the level of specific [<sup>125</sup>I]ET-1 binding was similar for COS-7 cells transfected with wild-type or Asp<sup>147</sup>Ala ET<sub>B</sub> receptors, consistent with equivalent receptor expression (Fig. 3B).

## 4. Discussion

Identification of receptor amino acids involved in ligand binding and signal transduction is a fundamental step in elucidating ligand-receptor-G protein interactions and in under-

Table 2

Inhibition of specific [<sup>125</sup>I]ET-1 binding (50 pM) to Asp<sup>147</sup>Ala, His<sup>150</sup>Ala, His<sup>150</sup>Tyr and Asp<sup>154</sup>Ala ET<sub>B</sub> receptor mutants

Agent	Wild-type ET <sub>B</sub>	Asp <sup>147</sup> Ala ET <sub>B</sub>	His <sup>150</sup> Ala ET <sub>B</sub>	His <sup>150</sup> Tyr ET <sub>B</sub>	Asp <sup>154</sup> Ala ET <sub>B</sub>
ET-1	0.2 ± 0.0	0.1 ± 0.02	0.2 ± 0.1	1.5 ± 0.1	0.1 ± 0.02
ET-3	0.4 ± 0.2	0.1 ± 0.03	1 ± 0.1	6 ± 0.4	0.2 ± 0.1
S6c	0.3 ± 0.1	1.2 ± 0.6	8 ± 1	50 ± 4	0.1 ± 0.03
BMS-182874	110,000 ± 27,000	> 50,000	> 50,000	> 50,000	> 50,000
Ro 47-0203	160 ± 40	95 ± 5	1,700 ± 400	700 ± 30	190 ± 20

Values are inhibition constants (IC<sub>50</sub>) in nM ± S.E.M. (n = 3–6). Binding to the wild-type receptor is shown for comparison.

standing the mechanisms by which GPCRs transduce signals from the extracellular to intracellular milieu. Several recent studies have begun to characterize residues in the ET receptors that are involved in agonist and antagonist binding [8–12] as well as in defining the subtype-selective ligand binding profile [13–14]. Less information is presently available on specific residues involved in signal transduction [31]. In the present study we demonstrate that the aspartate residues flanking Tyr<sup>129</sup> of ET<sub>A</sub> are involved in binding and PLC activation (Asp<sup>126</sup>) and that the corresponding aspartate (Asp<sup>147</sup>) in the ET<sub>B</sub> receptor are involved in signaling.

A significant finding from this study was the altered ligand binding profile of the Asp<sup>126</sup>Ala ET<sub>A</sub> mutant. While we had recently observed a 200-fold improvement in ET-3 affinity for the Tyr<sup>129</sup>Ala ET<sub>A</sub> receptor mutant [13], the observation that mutation of Asp<sup>126</sup>, a residue proposed to lie 13 amino acids within the TM2, similarly improves ET-3 affinity was unexpected. In the absence of ligand–receptor structure-activity data that would point clearly toward a direct ligand interaction with Asp<sup>126</sup>, and because our model suggests that Asp<sup>126</sup> is deep within the transmembrane region, we must consider the possibility that Asp<sup>126</sup> influences binding by affecting the position of the Tyr<sup>129</sup> side chain in the binding cavity rather than by directly interacting with a ligand. Recently, it has been shown that mutation of Tyr<sup>129</sup> to phenylalanine [14] as well as alanine [13,14] causes more than a 100-fold increase in ET-3 binding. Since ET-3 binding improved in the Tyr<sup>129</sup>Phe mutant, a direct, unfavorable interaction of ET-3 with the phenolic OH of the Tyr<sup>129</sup> is possible. However, in light of the present Asp<sup>126</sup>Ala data, another possibility is that the OH group of Tyr<sup>129</sup> is involved in specific interactions with Asp<sup>126</sup>. According to this view, the interaction of Asp<sup>126</sup> with the phenolic OH may constrain the orientation of Tyr<sup>129</sup>. Removal of the OH group, as in the Tyr<sup>129</sup>Phe mutant, or mutation of Asp<sup>126</sup> to alanine may alter these constraints and allow for steric rearrangements that result in improved ET-3 binding.

In contrast to ET-3, sarafotoxin S6c binding affinity to Asp<sup>126</sup>Ala receptors was not improved (Table 1). Sarafotoxin S6c and ET-3 are 50% homologous, suggesting that one or more of the non-conserved amino acid residues in ET-3 is responsible for the improved affinity for the Asp<sup>126</sup>Ala mutant receptor. In this regard, it is important to note that for both the Tyr<sup>129</sup>Ala and Asp<sup>126</sup>Ala mutants, the side chains of the native receptor were replaced with amino acids containing side chains of considerably less bulk. Correspondingly, ET-3 has amino acids of greater steric bulk at positions 4 and 5 when compared to ET-1, ET-2 and sarafotoxin S6c (Phe<sup>4</sup> and Thr<sup>5</sup> in ET-3 v Ser<sup>4</sup> and Ser<sup>5</sup> in ET-1 and ET-2 v Asn<sup>4</sup> and Asp<sup>5</sup> in sarafotoxin S6c). Thus, reduction in the bulk of receptor amino acids may contribute to the changes observed in ligand binding affinities. Additional experiments are necessary to precisely map the binding sites for the ET peptides.

Interaction with Asp<sup>133</sup> of ET<sub>A</sub> receptors appears not to be a general requirement for conferring the well-defined subtype-selectivity profile since only the affinity of BMS-182874 was altered in this mutant from wild-type ET<sub>A</sub> receptor values. Rather, it seems more likely that structural differences between BMS-182874 and BQ-123 lead to disparate contacts in the ET<sub>A</sub> receptor and that only BMS-182874 binding is dependent on the presence of Asp<sup>133</sup>. It is interesting to note that the pyrimidinyl naphthalenesulfonamide, Ro 47-0203, which binds to

ET<sub>A</sub> and ET<sub>B</sub> receptors with approximately equal affinity [6], had similar binding affinity for wild-type and Asp<sup>133</sup>Ala mutant ET<sub>A</sub> receptors. This may suggest that the decreased affinity of BMS-182874 for the Asp<sup>133</sup>Ala ET<sub>A</sub> mutant was specific for the ET<sub>A</sub> selective naphthalenesulfonamide series of antagonists.

That Asp<sup>126</sup> and Tyr<sup>129</sup> [13] appear to be important for the high affinity binding of ET-3 and BMS-182874 is consistent with the hypothesis that the binding sites for agonists and antagonists are, at least in part, overlapping. On the other hand, the data showing that Asp<sup>133</sup> is critical only for the high affinity binding of BMS-182874 suggests that the binding site for this antagonist is also, at least in part, distinct from the binding site for the peptides. This is reminiscent of the observation that agonists and antagonists bind differently to the AT1 angiotensin II [32], cholecystokinin-B/gastrin [33], neurokinin-1 [34–35] and bradykinin receptors [36]. Studies in progress that are aimed at docking ligands into the putative binding cavities of the ET receptors should yield more precise information on agonist and antagonist binding sites.

Asp<sup>126</sup> in ET<sub>A</sub> and Asp<sup>147</sup> in ET<sub>B</sub> receptors correspond to the aspartate residue in TM2 that is conserved in many GPCR [15]. This conserved aspartate has been shown to play a role in agonist binding and transmembrane signaling via G proteins in the  $\alpha$ 2-adrenergic [16], LH [17] and AT1 angiotensin II [18] receptors and has been implicated in the allosteric modulation of agonist binding in the  $\alpha$ 2-adrenergic [37], somatostatin type 2 [38] and serotonin receptors [39] by sodium ion. A significant finding from the present study was the requirement of Asp<sup>126</sup> in the ET<sub>A</sub> receptor and Asp<sup>147</sup> in the ET<sub>B</sub> receptor for PLC activation. Thus, agonist efficacy did not correlate with binding affinity in the Asp<sup>126</sup>Ala ET<sub>A</sub> or Asp<sup>147</sup>Ala ET<sub>B</sub> mutants as high affinity ET-1 and ET-3 binding is better than or comparable to that in wild-type receptors yet stimulation of IP accumulation was abolished. Because of the transient nature of receptor expression in these experiments, care was taken to concomitantly assess agonist binding and efficacy. In all experiments, specifically bound [<sup>125</sup>I]ET-1 to mutated ET<sub>A</sub> or ET<sub>B</sub> receptors was equal to or slightly greater than that to the corresponding wild-type ET receptors demonstrating that reduced efficacy was not due to reduced receptor expression. At present, it is not clear if the receptor mutations have an effect on G protein coupling or whether this in turn effects agonist binding. Such investigation is best conducted in mammalian cell lines that stably express the mutant receptors rather than the transient expression studied here. However, high concentrations (200  $\mu$ M) of the non-hydrolyzable guanine nucleotide, GTP $\gamma$ S, did not alter the binding affinity of ET-1 to transiently expressed wild-type or Asp<sup>126</sup>Ala ET<sub>A</sub> receptors (E.C.K. Liu and M.L. Webb, unpublished) suggesting that either most of the ET<sub>A</sub> receptors are already uncoupled from G-protein or that ET-1 binding is nucleotide independent.

In addition, the present study has demonstrated that, despite the 160-fold improvement in ET-3 affinity to the Asp<sup>126</sup>Ala mutant, the efficacy of this agonist remained ET<sub>B</sub>-like. Although the precise reason for this finding is unclear, these data are consistent with the suggestion that the removal or re-positioning of residues in TM2 that led to enhanced ET-3 binding, possibly through localized structural changes in the Asp<sup>126</sup>-Tyr<sup>129</sup>-Asp<sup>133</sup> region, are different from the receptor conformational changes that are necessary for signal transduction normally triggered by Asp<sup>126</sup>.

In summary and in combination with our previous studies [13], the present data demonstrate that the Asp<sup>126</sup>-Tyr<sup>129</sup>-Asp<sup>133</sup> turn in TM2 contributes to ET<sub>A</sub> receptor subtype-selective ligand binding, largely defined by Tyr<sup>129</sup>, and to transmembrane signal transduction. In contrast, whereas His<sup>150</sup> contributes to high affinity ET-3, sarafotoxin S6c and Ro 47-0203 binding, the corresponding aspartates in TM2 of the ET<sub>B</sub> receptor, Asp<sup>147</sup> and Asp<sup>154</sup>, are not involved in defining the agonist binding profile. Thus, a region that is critical in defining high affinity ligand binding and transmembrane signaling in ET<sub>A</sub> is involved predominantly in signaling in ET<sub>B</sub>.

**Acknowledgements:** We would like to thank Dr. Phil Stein for the synthesis of BMS-182874, Mr. Alan Fritz for BQ-123, Mr. Ving Lee for Ro 46-2005 and Mr. Toomas Mitt for Ro 47-0203, Ms. Bernadette Kienzle for DNA sequencing, Ms. Cathy Aversa for assistance with the CMV/β-gal assays, Ms. Ophelia Hadjilambris for assistance with optimization of transfection assays and Drs. Ken Carlson, Thomas Meek, Jiri Novotny and Phil Stein for critical discussions.

## References

- [1] Aramori, I. and Nagasaki, S. (1992) *J. Biol. Chem.* 267, 12468–12474.
- [2] Webb, M.L., Liu, E.C.-K., Monshizadegan, H., Chao, C.-C., Lynch, J., Fisher, S.M. and Rose, P.M. (1993) *Mol. Pharmacol.* 44, 959–965.
- [3] Ihara, M., Noguchi, K., Saeki, T., Fukuroda, T., Tsuchida, S., Kimura, S., Fukami, T., Ishikawa, K., Nishikibe, M. and Yano, M. (1992) *Life Sci.* 50, 247–255.
- [4] Stein, P.D., Hunt, J.T., Floyd, D.M., Moreland, S., Dickinson, K.E.J., Mitchell, C., Liu, E.C.-K., Webb, M.L., Murugesan, N., Dickey, J., McMullen, D., Zhang, R., Lee, V.G., Serafino, R., Delaney, C., Schaeffer, T.R. and Kozlowski, M. (1994) *J. Med. Chem.* 37, 329–331.
- [5] Clozel, M., Breu, V., Burri, K., Cassal, J.-M., Fischli, W., Gray, G.A., Hirth, G., Loffler, B.-M., Muller, M., Neidhart, W. and Ramuz, H. (1993) *Nature* 365, 759–761.
- [6] Clozel, M., Clozel, J.-P. and Hess, P. (1993) *Circulation* 88, 1316.
- [7] Elliott, J.D., Lago, M.A., Cousins, R.D., Gao, A. et al. (1994) *J. Med. Chem.* 37, 1553–1557.
- [8] Adachi, M., Yang, Y.-Y., Trzeciak, A., Furuichi, Y. and Miyamoto, C. (1992) *FEBS Lett.* 311, 179–183.
- [9] Sakamoto, A., Yanagisawa, M., Sawamura, T., Enoki, T., Ohtani, T., Sakurai, T., Nakao, K., Toyooka, T. and Masaki, T. (1993) *J. Biol. Chem.* 268, 8547–8553.
- [10] Takasuka, T., Sakurai, T., Goto, K., Furuichi, Y. and Watanabe, T. (1994) *J. Biol. Chem.* 269, 7509–7513.
- [11] Zhu, G., Wu, L.-H., Mauzy, C., Egloff, A.M. and Mirzadegan, T. (1992) *J. Cell. Biochem.* 50, 159–164.
- [12] Adachi, M., Furuichi, Y. and Miyamoto, C. (1994) *J. Biochem.* 220, 37–43.
- [13] Krystek, S., Patel, P.S., Rose, P.M., Fisher, S.M., Kienzle, B., Lach, D.A., Liu, E.C.-K., Lynch, J.S., Novotny, J. and Webb, M.L. (1994) *J. Biol. Chem.* 269, 12383–12386.
- [14] Lee, J.A., Elliott, J.D., Sutiphong, J.A., Friesen, W.J., Ohlstein, E.H., Stadel, J.M., Gleason, J.G. and Peishoff, C.E. (1994) *Proc. Natl. Acad. Sci. USA* 91, 7164–7168.
- [15] Probst, W.C., Snyder, L.A., Schuster, D.I., Brosius, J. and Sealfon, S.C. (1992) *DNA Cell Biol.* 11, 1–20.
- [16] Wang, C.-D., Buck, M.A. and Fraser, C.M. (1991) *Mol. Pharmacol.* 40, 168–179.
- [17] Ji, I. and Ji, T.H. (1991) *J. Biol. Chem.* 266, 14953–14957.
- [18] Bihoreau, C., Monnot, C., Davies, E., Teutsch, B., Bvernstein, K.E., Corvol, P. and Clauser, E. (1993) *Proc. Natl. Acad. Sci. USA* 90, 5133–5137.
- [19] Strader, C.D., Sigal, I.S., Candelore, M.R., Rands, E., Hill, W.S. and Dixon, R.A.F. (1988) *J. Biol. Chem.* 263, 10267–10271.
- [20] Kong, H., Raynor, K., Yasuda, K., Moe, S.T., Portoghese, P.S., Bell, G.I. and Reisine, T. (1993) *J. Biol. Chem.* 268, 23055–23058.
- [21] Henderson, R., Baldwin, J.M., Ceska, T.A., Zemlin, F., Beckmann, E. and Downing, K.H. (1990) *J. Mol. Biol.* 213, 899–929.
- [22] Nicholls, A., Sharp, K. and Honig, B. (1991) *Proteins: Structure, Function and Genetics* 11, 281.
- [23] Hayzer, D.J., Rose, P.M., Lynch, J.S., Webb, M.L., Kienzle, B.K., Liu, E.C.-K., Bogosian, E.A., Brinson, E. and Runge, M.S. (1992) *Am. J. Med. Sci.* 304, 231–238.
- [25] Wang, Y., Rose, P.M., Webb, M.L. and Dunn, M.J. (1994) *Am. J. Physiol.* 267, C1130–C1135.
- [26] Kunkel, T.A. (1985) *Proc. Natl. Acad. Sci. USA* 82, 488–492.
- [27] Sanger, F., Nicklen, S. and Coulson, A.R. (1987) *Proc. Natl. Acad. Sci. USA* 74, 5463–5467.
- [28] Berridge, M.J. (1983) *Biochem. J.* 212, 849–858.
- [29] Hutchins, C. (1994) *Endocrinol.* 7, 2–23.
- [30] Webb, M.L., Bird, J.E., Liu, E.C.-K., Rose, P.M., Serafino, R., Stein, P.D. and Moreland, S. (1995) *J. Pharmacol. Exp. Therap.* (in press).
- [31] Hashido, K., Adachi, M., Gamou, T., Watanabe, T., Furuichi, Y. and Miyamoto, C. (1993) *Cell. Mol. Biol. Res.* 39, 3–12.
- [32] Ji, H., Leung, M., Zhang, Y., Catt, K.J. and Sandberg, K. (1994) *J. Biol. Chem.* 269, 16533–16536.
- [33] Beinborn, M., Lee, Y.M., McBride, E.W., Quinn, S.M. and Kopin, A.S. (1993) *Nature* 362, 348–350.
- [34] Fong, T.M., Cascieri, M.A., Yu, H., Bansal, A., Swain, C. and Strader, C.D. (1993) *Nature* 362, 350–353.
- [35] Gether, J., Johansen, T.E., Snider, R.M., Lowe, J.A., Nakanishi, S. and Schwartz, T.W. (1993) *Nature* 362, 345–348.
- [36] Nardone, J. and Hogan, P.G. (1994) *Proc. Natl. Acad. Sci. USA* 91, 4417–4421.
- [37] Horstman, D.A., Brandon, S., Wilson, A.L., Guyer, C.A., Cragoe, E.J. and Limbird, L.E. (1990) *J. Biol. Chem.* 265, 21590–21595.
- [38] Kong, H., Raynor, K., Yasuda, K., Bell, G.I. and Reisine, T. (1993) *Mol. Pharmacol.* 44, 380–384.
- [39] Parker, E.M., Grisel, D.A., Iben, L.G., Nowak, H.P., Mahle, C.D., Yocca, F.D. and Gaughan, G.T. (1994) *Eur. J. Pharmacol.* 268, 43–5322.